Hubei Biocause Pharmaceutical (000627) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.008x

Based on the latest financial reports, Hubei Biocause Pharmaceutical (000627) has a cash flow conversion efficiency ratio of 0.008x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥276.06 Million ≈ $40.40 Million USD) by net assets (CN¥33.70 Billion ≈ $4.93 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Hubei Biocause Pharmaceutical - Cash Flow Conversion Efficiency Trend (2001–2023)

This chart illustrates how Hubei Biocause Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 000627 total liabilities for a breakdown of total debt and financial obligations.

Hubei Biocause Pharmaceutical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hubei Biocause Pharmaceutical ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
MASTERBRAND INC. DL-001 F:D55	N/A
AS LHV GROUP EO -10 F:ASU0	N/A
CONMED Corporation NYSE:CNMD	0.045x
Atresmedia Corporación de Medios de Comunicación S.A. MC:A3M	0.036x
Hangzhou Greenda Electronic Materials Co Ltd SHG:603931	0.035x
China Reform Health Management and Services Group Co Ltd SHE:000503	-0.050x
Decai Decoration Co Ltd SHG:605287	0.009x
Kumho Tire KO:073240	0.178x

Annual Cash Flow Conversion Efficiency for Hubei Biocause Pharmaceutical (2001–2023)

The table below shows the annual cash flow conversion efficiency of Hubei Biocause Pharmaceutical from 2001 to 2023. For the full company profile with market capitalisation and key ratios, see Hubei Biocause Pharmaceutical market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2023-12-31	CN¥33.63 Billion ≈ $4.92 Billion	CN¥9.53 Billion ≈ $1.40 Billion	0.283x	+30.37%
2022-12-31	CN¥34.60 Billion ≈ $5.06 Billion	CN¥7.52 Billion ≈ $1.10 Billion	0.217x	+95.29%
2021-12-31	CN¥37.47 Billion ≈ $5.48 Billion	CN¥4.17 Billion ≈ $610.58 Million	0.111x	-82.02%
2020-12-31	CN¥34.59 Billion ≈ $5.06 Billion	CN¥21.42 Billion ≈ $3.13 Billion	0.619x	-25.61%
2019-12-31	CN¥34.35 Billion ≈ $5.03 Billion	CN¥28.60 Billion ≈ $4.19 Billion	0.833x	+44.56%
2018-12-31	CN¥26.01 Billion ≈ $3.81 Billion	CN¥14.98 Billion ≈ $2.19 Billion	0.576x	+3463.41%
2017-12-31	CN¥26.70 Billion ≈ $3.91 Billion	CN¥431.58 Million ≈ $63.15 Million	0.016x	+114.07%
2016-12-31	CN¥20.40 Billion ≈ $2.98 Billion	CN¥-2.34 Billion ≈ $-342.76 Million	-0.115x	-338.31%
2015-12-31	CN¥1.78 Billion ≈ $261.01 Million	CN¥-46.73 Million ≈ $-6.84 Million	-0.026x	-128.83%
2013-12-31	CN¥1.44 Billion ≈ $210.17 Million	CN¥130.53 Million ≈ $19.10 Million	0.091x	+48.97%
2012-12-31	CN¥1.54 Billion ≈ $224.96 Million	CN¥93.79 Million ≈ $13.72 Million	0.061x	+28.87%
2011-12-31	CN¥1.41 Billion ≈ $206.93 Million	CN¥66.95 Million ≈ $9.80 Million	0.047x	-66.23%
2010-12-31	CN¥1.60 Billion ≈ $234.43 Million	CN¥224.58 Million ≈ $32.86 Million	0.140x	+2.40%
2007-12-31	CN¥866.03 Million ≈ $126.73 Million	CN¥118.56 Million ≈ $17.35 Million	0.137x	-22.71%
2006-12-31	CN¥723.71 Million ≈ $105.90 Million	CN¥128.19 Million ≈ $18.76 Million	0.177x	+166.20%
2005-12-31	CN¥731.23 Million ≈ $107.00 Million	CN¥48.66 Million ≈ $7.12 Million	0.067x	-14.08%
2004-12-31	CN¥723.91 Million ≈ $105.93 Million	CN¥56.07 Million ≈ $8.20 Million	0.077x	+58.41%
2001-12-31	CN¥762.99 Million ≈ $111.65 Million	CN¥37.30 Million ≈ $5.46 Million	0.049x	--

About Hubei Biocause Pharmaceutical

SHE:000627 China Insurance - Life

Market Cap

$1.13 Billion

CN¥7.75 Billion CNY

Market Cap Rank

#8572 Global

#2236 in China

Share Price

CN¥1.58

Change (1 day)

+0.00%

52-Week Range

CN¥1.39 - CN¥2.74

All Time High

CN¥10.45